You have 9 free searches left this month | for more free features.

Cetuximab

Showing 1 - 25 of 1,156

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Metastatic Colorectal Cancer Trial (Cetuximab + Envafolimab + mFOLFOXIRI, Cetuximab + mFOLFOX6/FOLFIRI)

Not yet recruiting
  • Metastatic Colorectal Cancer
  • Cetuximab + Envafolimab + mFOLFOXIRI
  • Cetuximab + mFOLFOX6/FOLFIRI
  • (no location specified)
Jul 24, 2023

Locally Advanced Hypopharyngeal Carcinoma Trial in Shanghai (drug, procedure, radiation)

Not yet recruiting
  • Locally Advanced Hypopharyngeal Carcinoma
  • three cycles (toripalimab + cetuximab + platinum)
  • +2 more
  • Shanghai, Shanghai, China
    Eye & ENT Hospital of Fudan University
Nov 22, 2023

Metastatic Colorectal Cancer, Cetuximab, Skin Toxicity Trial in Guangzhou (Crisaborole Ointment, Cetuximab)

Recruiting
  • Metastatic Colorectal Cancer
  • +2 more
  • Crisaborole Ointment
  • Cetuximab
  • Guangzhou, Guangdong, China
    WeiWei Xiao
Nov 3, 2023

Squamous Cell Carcinoma of the Head and Neck Trial (Xevinapant, Placebo, cetuximab)

Not yet recruiting
  • Squamous Cell Carcinoma of the Head and Neck
  • (no location specified)
Jul 3, 2023

Metastatic Colorectal Cancer Trial in Houston (Cetuximab, Ulixertinib, Encorafenib)

Not yet recruiting
  • Metastatic Colorectal Cancer
  • Cetuximab
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Aug 9, 2023

Advanced Colorectal Cancer Trial in Hangzhou (Cetuximab Dabrafenib Tislelizumab)

Not yet recruiting
  • Advanced Colorectal Cancer
  • Cetuximab Dabrafenib Tislelizumab
  • Hangzhou, Zhejing, China
    Zhejiang Cancer Institute & Hospital
Jul 19, 2023

Metastatic Colorectal Cancer Trial (Cetuximab and irinotecan)

Not yet recruiting
  • Metastatic Colorectal Cancer
  • Cetuximab and irinotecan
  • (no location specified)
Jul 26, 2023

Metastatic Colorectal Adenocarcinoma, Refractory Colorectal Adenocarcinoma, Stage IV Colorectal Cancer AJCC v8 Trial (drug,

Not yet recruiting
  • Metastatic Colorectal Adenocarcinoma
  • +2 more
  • BET Bromodomain Inhibitor ZEN-3694
  • +6 more
  • (no location specified)
Oct 25, 2023

Colorectal Cancer Liver Metastases Trial in Shanghai (Cetuximab)

Not yet recruiting
  • Colorectal Cancer Liver Metastases
  • Cetuximab
  • Shanghai, Shanghai, China
  • +1 more
May 22, 2023

Colorectal Cancer, Liver Metastases Trial in Shanghai (mFOLFOX6 + Cetuximab, mFOLFOX 6)

Not yet recruiting
  • Colorectal Cancer
  • Liver Metastases
  • mFOLFOX6 + Cetuximab
  • mFOLFOX 6
  • Shanghai, China
    Zhongshan hosptial, Fudan University
Jul 14, 2023

Lung Cancer, Video-assisted Thoracic Surgery, EGFR Trial in Torino (Cetuximab-IRDye800)

Not yet recruiting
  • Lung Cancer
  • +3 more
  • Torino, TO, Italy
    Azienda Ospedaliera Universitaria Città della Salute e della Sci
Oct 23, 2023

Glioblastoma, High-grade Glioma Trial in Groningen (Cetuximab-IRDye800)

Recruiting
  • Glioblastoma
  • High-grade Glioma
  • Groningen, Netherlands
    UMCG
Jun 26, 2023

Hend and Neck Squamous Cell Carcinoma Locally Advanced Operable Trial in Guangzhou (Cetuximab, Zimberelimab, Docetaxel)

Not yet recruiting
  • Hend and Neck Squamous Cell Carcinoma Locally Advanced Operable
  • Cetuximab
  • +3 more
  • Guangzhou, Guangdong, China
    Sun Yat-sen University
Oct 24, 2023

Metastatic Head-and-neck Squamous-cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma Trial (Ficlatuzumab,

Not yet recruiting
  • Metastatic Head-and-neck Squamous-cell Carcinoma
  • Recurrent Head and Neck Squamous Cell Carcinoma
  • Ficlatuzumab
  • +2 more
  • (no location specified)
Sep 26, 2023

Squamous Cell Carcinoma of Head and Neck Trial in Hangzhou (Toripalimab)

Recruiting
  • Squamous Cell Carcinoma of Head and Neck
  • Hangzhou, Zhejiang, China
    Department of Medical Onocology, First Affiliated Hospital of Zh
Oct 7, 2023

Head Neck, Squamous Cell Carcinoma of Head and Neck Trial in Houston (Pembrolizumab, Magrolimab, cetuximab)

Not yet recruiting
  • Head Neck
  • Squamous Cell Carcinoma of Head and Neck
  • Houston, Texas
    M D Anderson Cancer Center
Sep 14, 2023

Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8 Trial in

Not yet recruiting
  • Metastatic Lung Non-Small Cell Carcinoma
  • +2 more
  • Cetuximab
  • +2 more
  • Sacramento, California
    University of California Davis Comprehensive Cancer Center
Oct 2, 2023

Colorectal Cancer Trial (Tislelizumab, Irinotecan Hydrochloride, cetuximab)

Not yet recruiting
  • Colorectal Cancer
  • (no location specified)
Mar 23, 2023

Head and Neck Squamous Cell Carcinoma, Neoadjuvant Therapy Trial in Wuhan (drug, procedure, radiation)

Not yet recruiting
  • Head and Neck Squamous Cell Carcinoma
  • Neoadjuvant Therapy
  • 3cycles (Toripalimab + cetuximab)
  • +2 more
  • Wuhan, Hebei, China
    Union Hospital, Tongji Medical College, Huazhong University of S
Aug 6, 2023

Advance NSCLC Trial (GFH925, Cetuximab)

Not yet recruiting
  • Advance Non-small Cell Lung Cancer
  • (no location specified)
Mar 7, 2023

Metastatic Colorectal Cancer Trial in Guangzhou (Cetuximab, Capecitabine)

Recruiting
  • Metastatic Colorectal Cancer
  • Guangzhou, Guangdong, China
    The Sixth Affiliated Hospital of Sun Yat-sen University
Mar 7, 2023

Advanced or Metastatic Squamous NSCLC Trial in Sydney (HMBD-001, Docetaxel, Cetuximab)

Not yet recruiting
  • Advanced or Metastatic Squamous Non-Small Cell Lung Cancer
  • Sydney, New South Wales, Australia
    GenesisCare North Shore
Jun 20, 2023

Cancer of Colon Trial in Jerusalem (Cetuximab)

Terminated
  • Cancer of Colon
  • Cetuximab
  • Jerusalem, Israel
    Hadassah Ein Kerem
Aug 2, 2022

Colon Adenocarcinoma, Microsatellite Stable Colon Carcinoma, Stage IIB Colon Cancer AJCC v8 Trial (drug, biological, procedure,

Not yet recruiting
  • Colon Adenocarcinoma
  • +4 more
  • (no location specified)
Jan 24, 2023

Colon Cancer, Colorectal Cancer Trial in Houston (MRTX849, Irinotecan, Cetuximab)

Not yet recruiting
  • Colon Cancer
  • Colorectal Cancer
  • Houston, Texas
    M D Anderson Cancer Center
Feb 1, 2023